Summary:
In adults with obesity-related heart failure with preserved ejection fraction (HFpEF), semaglutide 2.4 mg administered weekly for 52 weeks significantly reduced body weight (-8.8% to -6.9%), improved health status (+9.3 vs. +4.7 KCCQ points), enhanced exercise capacity, and decreased loop diuretic use by 17% compared to placebo administered weekly alongside standard care, though it was associated with no significant adverse safety signals.
PICO | Description |
---|---|
Population | Adults with obesity-related heart failure with preserved ejection fraction (HFpEF) and body mass index (BMI) ≥ 30 kg/m² from the pooled STEP-HFpEF and STEP-HFpEF-DM trials (n = 1,145), classified by baseline diuretic use (no diuretics, non-loop diuretics, and loop diuretics). |
Intervention | Weekly administration of semaglutide 2.4 mg for 52 weeks in addition to standard care for heart failure with preserved ejection fraction (HFpEF). |
Comparison | Placebo administered weekly for 52 weeks along with standard care; data analyzed based on participants’ baseline diuretic use and dose adjustments over the treatment period. |
Outcome | Semaglutide resulted in consistent, significant weight reduction across all diuretic subgroups (mean difference ranged from -8.8% to -6.9%), improved Kansas City Cardiomyopathy Questionnaire scores (more pronounced improvements in loop diuretic users; +9.3 vs. +4.7 points vs. placebo). Exercise capacity (6-min walk distance) and other secondary efficacy endpoints also improved. Safety measures favored semaglutide, and its use reduced loop diuretic doses by 17%, compared to the placebo group’s 2.4% increase (P < .0001). |
Source: Jastreboff, Amy, et al. “Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM Trials.” PMC. Read article here.
This PICO summary was generated through the collaborative efforts of Hormone Insight’s artificial intelligence system and underwent expert clinical review to ensure accuracy and relevance.